Medication review with follow-up for cardiovascular outcomes: a trial based cost-utility analysis.

Ahumada-Canale, A; Vargas, C; Balmaceda, C; Martinez-Mardones, F; Plaza-Plaza, JC; Benrimoj, S; Garcia-Cardenas, V

Medication review with follow-up for cardiovascular outcomes: a trial based cost-utility analysis.

Ahumada-Canale, A Vargas, C Balmaceda, C Martinez-Mardones, F Plaza-Plaza, JC Benrimoj, S Garcia-Cardenas, V

Permalink

Publisher:: Future Science Group
Publication Type:: Journal Article
Citation:: Journal of Comparative Effectiveness Research, 2021, 10, (3), pp. 229-242
Issue Date:: 2021-02-05

Closed Access

	Filename	Description	Size
	Medication_review_with_follow-.pdf		1.81 MB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Ahumada-Canale, A
dc.contributor.author	Vargas, C
dc.contributor.author	Balmaceda, C
dc.contributor.author	Martinez-Mardones, F
dc.contributor.author	Plaza-Plaza, JC
dc.contributor.author	Benrimoj, S
dc.contributor.author	Garcia-Cardenas, V
dc.date.accessioned	2021-11-04T05:52:25Z
dc.date.available	2021-11-04T05:52:25Z
dc.date.issued	2021-02-05
dc.identifier.citation	Journal of Comparative Effectiveness Research, 2021, 10, (3), pp. 229-242
dc.identifier.issn	2042-6313
dc.identifier.issn	2042-6313
dc.identifier.uri	http://hdl.handle.net/10453/151341
dc.description.abstract	Aim: To assess the trial-based cost–effectiveness of medication review with follow-up compared with usual care in primary care. Materials & methods: A cluster randomized controlled trial included patients if they were independent older adults, receiving five or more prescriptions, with moderate or high cardiovascular risk. Costs were estimated from the public healthcare sector perspective, and health benefits were measured as quality-adjusted life years. Both of which were used to calculate the incremental cost–effectiveness ratio. Results: Twelve centers completed the study, six (146 patients) in the intervention group and six (145 patients) in the control group. The base-case analysis showed an incremental cost–effectiveness ratio of US$ (2019) 434.4/quality-adjusted life year (95% CI 64.20–996.03). Conclusion: The intervention was cost-effective in the public primary care setting.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	Future Science Group
dc.relation.ispartof	Journal of Comparative Effectiveness Research
dc.relation.isbasedon	10.2217/cer-2020-0171
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject.mesh	Aged
dc.subject.mesh	Cost-Benefit Analysis
dc.subject.mesh	Follow-Up Studies
dc.subject.mesh	Humans
dc.subject.mesh	Primary Health Care
dc.subject.mesh	Quality of Life
dc.subject.mesh	Quality-Adjusted Life Years
dc.subject.mesh	Humans
dc.subject.mesh	Follow-Up Studies
dc.subject.mesh	Quality-Adjusted Life Years
dc.subject.mesh	Quality of Life
dc.subject.mesh	Aged
dc.subject.mesh	Cost-Benefit Analysis
dc.subject.mesh	Primary Health Care
dc.subject.mesh	Aged
dc.subject.mesh	Cost-Benefit Analysis
dc.subject.mesh	Follow-Up Studies
dc.subject.mesh	Humans
dc.subject.mesh	Primary Health Care
dc.subject.mesh	Quality of Life
dc.subject.mesh	Quality-Adjusted Life Years
dc.title	Medication review with follow-up for cardiovascular outcomes: a trial based cost-utility analysis.
dc.type	Journal Article
utslib.citation.volume	10
utslib.location.activity	England
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
pubs.organisational-group	/University of Technology Sydney/Strength - CHERE - Centre for Health Economics Research and Evaluation
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health/GSH.Pharmacy
utslib.copyright.status	closed_access	*
pubs.consider-herdc	false
dc.date.updated	2021-11-04T05:52:23Z
pubs.issue	3
pubs.publication-status	Published
pubs.volume	10
utslib.citation.issue	3

Abstract:

Aim: To assess the trial-based cost–effectiveness of medication review with follow-up compared with usual care in primary care. Materials & methods: A cluster randomized controlled trial included patients if they were independent older adults, receiving five or more prescriptions, with moderate or high cardiovascular risk. Costs were estimated from the public healthcare sector perspective, and health benefits were measured as quality-adjusted life years. Both of which were used to calculate the incremental cost–effectiveness ratio. Results: Twelve centers completed the study, six (146 patients) in the intervention group and six (145 patients) in the control group. The base-case analysis showed an incremental cost–effectiveness ratio of US$ (2019) 434.4/quality-adjusted life year (95% CI 64.20–996.03). Conclusion: The intervention was cost-effective in the public primary care setting.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/151341